Sugi Predict

Sugi Predict / Compounds / SCHEMBL8515787

SCHEMBL8515787

SCHEMBL8515787

CC(C)(C)OC(=O)NC1CCN(c2cncc(Cl)n2)CC1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CKS1B P61024 3/20 0.61
▸ SKP1 P63208 3/20 0.61
▸ SKP2 Q13309 3/20 0.61
▸ JAK3 P52333 1/20 0.51
▸ BTK Q06187 1/20 0.51
▸ SUV39H2 Q9H5I1 7/20 0.49
▸ DRD2 P14416 2/20 0.44
▸ CNR1 P21554 1/20 0.44
▸ CNR2 P34972 1/20 0.44
▸ KDM4E B2RXH2 1/20 0.44
▸ MEN1 O00255 1/20 0.44
▸ ALDH1A1 P00352 1/20 0.44
▸ CYP1A2 P05177 1/20 0.44
▸ CYP3A4 P08684 1/20 0.44
▸ HTR1A P08908 1/20 0.44
▸ CYP2C9 P11712 1/20 0.44
▸ HPGD P15428 1/20 0.44
▸ HTR2A P28223 1/20 0.44
▸ HTR2C P28335 1/20 0.44
▸ CYP2C19 P33261 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL38666481 0.93 JAK3 (0.59) CKS1BSKP1SKP2JAK3BTK
SCHEMBL38663924 0.93 JAK3 (0.59) CKS1BSKP1SKP2JAK3BTK
SCHEMBL7384523 0.93 JAK3 (0.59) CKS1BSKP1SKP2JAK3BTK
SCHEMBL38665065 0.93 JAK3 (0.59) CKS1BSKP1SKP2JAK3BTK
SCHEMBL15446068 0.88 CKS1B (0.61) CKS1BSKP1SKP2JAK3BTK
SCHEMBL17108790 0.88 JAK3 (0.53) CKS1BSKP1SKP2JAK3BTK
SCHEMBL38663157 0.86 BTK (0.68) CKS1BSKP1SKP2JAK3BTK
SCHEMBL9900659 0.86 BTK (0.68) CKS1BSKP1SKP2JAK3BTK
SCHEMBL31080822 0.86 BTK (0.68) CKS1BSKP1SKP2JAK3BTK
SCHEMBL9900373 0.85 CKS1B (0.58) CKS1BSKP1SKP2JAK3BTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026106389-A1 NMT INHIBITOR AND USE THEREOF 주식회사 이노보테라퓨틱스 2026-05-21 — — WO disclosed
EP-4695238-A1 CDK2 INHIBITORS Blueprint Medicines Corporation (US) 2026-02-18 — — EP disclosed
WO-2024216154-A1 CDK2 INHIBITORS BLUEPRINT MEDICINES CORPORATION (US) 2024-10-17 — — WO disclosed
EP-3189038-B1 INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 CELGENE QUANTICEL RES INC (US) 2022-11-23 — — EP disclosed
CN-112125901-A Inhibitors of lysine-specific demethylase-1 赛尔基因昆蒂赛尔研究公司 2020-12-25 — — CN disclosed
US-10864202-B2 Inhibitors of lysine specific demethylase-1 CELGENE QUANTICEL RESEARCH, INC. (US) 2020-12-15 — — US disclosed
US-10864202-B2 Inhibitors of lysine specific demethylase-1 CELGENE QUANTICEL RESEARCH, INC. (US) 2020-12-15 — — US disclosed
CN-107074787-B Inhibitors of lysine-specific demethylase-1 赛尔基因昆蒂赛尔研究公司 2020-10-27 — — CN disclosed
US-20200108052-A1 INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 CELGENE QUANTICEL RESEARCH, INC. (US) 2020-04-09 — — US disclosed
US-10543198-B2 Inhibitor of lysine specific demethylase-1 CELGENE QUANTICEL RESEARCH, INC. (US) 2020-01-28 — — US disclosed
US-8318723-B2 Pyrazine compounds, their use and methods of preparation BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-11-27 — — US disclosed
WO-2012069852-A1 PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF SPHINGOSINE KINASE ALMAC DISCOVERY LIMITED (GB) 2012-05-31 — — WO disclosed
EP-2061762-B1 PYRAZINE COMPOUNDS, THEIR USE AND METHODS OF PREPARATION BOEHRINGER INGELHEIM INT (DE) 2011-07-27 — — EP disclosed
US-7858786-B2 Pyrimidines and pyrazines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCOROPATED (US) 2010-12-28 — — US disclosed
US-7858786-B2 Pyrimidines and pyrazines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCOROPATED (US) 2010-12-28 — — US disclosed
US-20100210627-A1 PYRAZINE COMPOUNDS, THEIR USE AND METHODS OF PREPARATION BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-08-19 — — US disclosed
US-20100210627-A1 PYRAZINE COMPOUNDS, THEIR USE AND METHODS OF PREPARATION BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-08-19 — — US disclosed
WO-2008022164-A2 PYRAZINE COMPOUNDS, THEIR USE AND METHODS OF PREPARATION BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-02-21 — — WO disclosed
US-20070093454-A1 Pyrimidines and pyrazines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED 2007-04-26 — — US disclosed
US-20070093454-A1 Pyrimidines and pyrazines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED 2007-04-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200108052-A1 INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 KDM1B, KDM1A, KDM3A CKS1B 317/4885SKP1 1075/4885SKP2 448/4885
US-10864202-B2 Inhibitors of lysine specific demethylase-1 KDM1B, KDM1A, KDM3A CKS1B 317/4885SKP1 1075/4885SKP2 448/4885
US-20070093454-A1 Pyrimidines and pyrazines useful as modulators of ion channels KCNJ1, KCNJ2, KCNJ11 CKS1B 2173/4885SKP1 1399/4885SKP2 1603/4885
US-20100210627-A1 PYRAZINE COMPOUNDS, THEIR USE AND METHODS OF PREPARATION CDK2, PIM1, CCNK CKS1B 36/4885SKP1 26/4885SKP2 25/4885
US-10543198-B2 Inhibitor of lysine specific demethylase-1 KDM1B, KDM1A, KDM3A CKS1B 316/4885SKP1 1014/4885SKP2 411/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.